Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report published on Wednesday. The firm issued a hold rating on the stock.

Several other research analysts have also weighed in on ONCT. Northland Capmk lowered shares of Oncternal Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, September 12th. Brookline Capital Management reiterated a hold rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. HC Wainwright dropped their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a research note on Monday, August 12th. Finally, Northland Securities reiterated a market perform rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and an average target price of $20.00.

Oncternal Therapeutics Price Performance

ONCT stock opened at $1.25 on Wednesday. Oncternal Therapeutics has a 52-week low of $1.20 and a 52-week high of $13.14. The company’s 50 day simple moving average is $3.63 and its 200-day simple moving average is $6.66. The firm has a market capitalization of $3.70 million, a P/E ratio of -0.10 and a beta of 1.36.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.14. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same quarter in the prior year, the business earned ($3.00) EPS. Sell-side analysts predict that Oncternal Therapeutics will post -11.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.